ABT Q4 Deep Dive: Nutrition Weakness and Innovation Shape 2026 OutlookHealthcare product and device company Abbott Laboratories (
NYSE:ABT) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit of $1.50 per share was in line with analysts’ consensus estimates.
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics WeaknessAbbott Laboratories (
NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting bottom-line expectations for earnings per share, the healthcare giant reported a significant revenue miss that spooked investors, driven primarily by
Why Abbott Laboratories (ABT) Shares Are Sliding TodayShares of healthcare product and device company Abbott Laboratories (
NYSE:ABT)
fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's expectations.
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings BeatAbbott Laboratories (
NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an adjusted earnings per share (EPS) of $1.50—narrowly edging out the $1.49 consensus estimate—the medical device giant’
Abbott Laboratories (NYSE:ABT) Misses Q4 CY2025 Revenue Estimates, Stock DropsHealthcare product and device company Abbott Laboratories (
NYSE:ABT) fell short of the markets revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit of $1.50 per share was in line with analysts’ consensus estimates.
Abbott Laboratories (ABT) Q4 Earnings Report Preview: What To Look ForHealthcare product and device company Abbott Laboratories (
NYSE:ABT)
will be announcing earnings results tomorrow before the bell. Here’s what to look for.
What To Expect From Abbott Laboratories’s (ABT) Q4 EarningsHealthcare product and device company Abbott Laboratories (
NYSE:ABT)
will be reporting earnings this Thursday before market open. Here’s what to look for.
$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A TransformationThe global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase, signaling a definitive end to the stagnation that plagued 2023 and 2024. As of January 19, 2026, the financial
1 Healthcare Stock to Consider Right Now and 2 We Find RiskyFrom novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 21.1% gain over the past six months, beating the S&P 500 by 10.6 percentage points.
The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&AAs 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to ReboundFor the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a resilient tech economy, healthcare investors were left nursing a "double-digit hangover." In 2024,
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 GrowthIn a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to ProfitabilityOn January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025 financial results that comfortably beat both internal guidance and Wall Street estimates. The Colorado-based lung diagnostics specialist reported a
